论文部分内容阅读
目的探讨瑞舒伐他汀对不稳定型心绞痛患者血脂及hs-CRP水平的影响。方法选择符合研究标准的2013年2月—2014年12月收治的100例不稳定型心绞痛患者,随机分组对照组50例,观察组50例。对照组:接受不稳定型心绞痛的常规治疗。观察组:接受不稳定型心绞痛常规治疗的同时口服瑞舒伐他汀。比较两组疗效,观察治疗前后两组患者血脂各项指标的变化,观察治疗前后两组患者hs-CRP水平的变化。结果治疗后观察组、对照组的的总有效率分别为92.0%、78.0%,两组相比差异显著(P<0.05)。观察组患者TC、TG、LDL等血脂指标水平均低于对照组,差异显著(P<0.05)。两组治疗后,观察组的hs-CRP水平低于对照组患者的hs-CRP,差异具有统计学意义(P<0.05)。结论瑞舒伐他汀治疗不稳定型心绞痛疗效确切,能够有效调节患者的血脂水平、减轻局部炎症反应,具有十分高的临床应用价值。
Objective To investigate the effects of rosuvastatin on serum lipids and hs-CRP levels in patients with unstable angina pectoris. Methods A total of 100 patients with unstable angina pectoris who were admitted to our hospital from February 2013 to December 2014 in our hospital were selected and randomly divided into control group (n = 50) and observation group (n = 50). Control group: receiving routine treatment of unstable angina pectoris. Observation group: Rosuvastatin orally was given while receiving conventional treatment of unstable angina pectoris. The curative effect of the two groups was compared, the changes of the indexes of blood lipid in the two groups before and after treatment were observed, and the changes of hs-CRP level in both groups before and after treatment were observed. Results After treatment, the total effective rates of the observation group and the control group were 92.0% and 78.0% respectively, with significant difference between the two groups (P <0.05). The levels of TC, TG and LDL in the observation group were significantly lower than those in the control group (P <0.05). After treatment, the hs-CRP level in the observation group was lower than that in the control group (P <0.05). Conclusion Rosuvastatin is effective in treating unstable angina pectoris, which can effectively regulate the level of blood lipids in patients and reduce the local inflammatory response, and has a very high clinical value.